

# MEDICAL ONCOLOGY

## Certification Examination (CERT)



High Relevance: Topics are very likely to appear on the assessment.

Medium Relevance: Topics are moderately likely to appear on the assessment.

Low Relevance: Topics will not appear on the assessment.

| Blueprint Code and Topic  | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | Risk Assessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|---|-----------------------|------------------------|-------------------------------|--|-----------------------------------|
| <b>1 Clinical Research Methodology and Ethics</b>                       | <b>6.5%</b>           |                        |                               |  |                                   |
| <b>1.1 Clinical research methodology</b>                                | 4.5%                  | <b>HIGH</b>            | <b>HIGH</b>                   | <b>HIGH</b>                                  | <b>HIGH</b>                       |
| 1.1.1 Design and interpretation of clinical trials                      |                       |                        |                               |  |                                   |
| 1.1.1.1 Clinical trial design   |                       |                        |                               |  |                                   |
| 1.1.1.2 Clinical trial interpretation                                   |                       |                        |                               |  |                                   |
| 1.1.2 Tumor assessment, imaging, and end points                         |                       |                        |                               |  |                                   |
| <b>1.2 Ethics</b>   | 2%                    | <b>HIGH</b>            | <b>HIGH</b>                   | <b>HIGH</b>                                  | LOW                               |
| 1.2.1 Human subjects and regulatory and legal issues                    |                       |                        |                               |  |                                   |
| 1.2.2 Conflict of interest  |                       |                        |                               |  |                                   |
| <b>2 Palliative Care, Survivorship, and Oncologic Complications</b>     | <b>11%</b>            |                        |                               |  |                                   |
| <b>2.1 Clinical manifestations of advanced cancer and its treatment</b> | 2.5%                  | <b>HIGH</b>            | <b>HIGH</b>                   | <b>HIGH</b>                                  | <b>HIGH</b>                       |
| 2.1.1 Cutaneous and mucosal manifestations                              |                       |                        |                               |  |                                   |
| 2.1.2 Endocrine manifestations  |                       |                        |                               |  |                                   |
| 2.1.3 Gastrointestinal manifestations                                   |                       |                        |                               |  |                                   |
| 2.1.4 Hematologic manifestations  |                       |                        |                               |  |                                   |
| 2.1.5 Musculoskeletal manifestations                                    |                       |                        |                               |  |                                   |
| 2.1.6 Neurologic manifestations   |                       |                        |                               |  |                                   |
| 2.1.7 Renal, metabolic, and nutritional manifestations                  |                       |                        |                               |  |                                   |
| 2.1.8 Paraneoplastic syndromes  |                       |                        |                               |  |                                   |
| 2.1.9 Cardiothoracic manifestations                                     |                       |                        |                               |  |                                   |
| 2.1.10 Fatigue  |                       |                        |                               |  |                                   |
| 2.1.11 Psychiatric manifestations                                       |                       |                        |                               |  |                                   |
| 2.1.12 Infectious risks and complications                               |                       |                        |                               |  |                                   |
| 2.1.13 Lymphedema   |                       |                        |                               |  |                                   |
| <b>2.2 Cancer pain</b>  | 3.5%                  | LOW                    | <b>HIGH</b>                   | <b>HIGH</b>                                  | <b>HIGH</b>                       |
| 2.2.1 Use of opioids  |                       |                        |                               |  |                                   |
| 2.2.2 Use of nonopioids   |                       |                        |                               |  |                                   |
| <b>2.3 Survivorship issues</b>  | <2%                   | <b>HIGH</b>            | <b>HIGH</b>                   | <b>HIGH</b>                                  | MEDIUM                            |
| 2.3.1 Fertility and sexual health                                       |                       |                        |                               |  |                                   |
| 2.3.2 Second primary cancers  |                       |                        |                               |  |                                   |
| 2.3.3 Secondary cancer prevention                                       |                       |                        |                               |  |                                   |
| 2.3.4 Nonmalignant sequelae   |                       |                        |                               |  |                                   |
| 2.3.5 Surveillance  |                       |                        |                               |  |                                   |
| <b>2.4 End-of-life issues</b>   | 2%                    | <b>HIGH</b>            | <b>HIGH</b>                   | <b>HIGH</b>                                  | MEDIUM                            |
| 2.4.1 Hospice   |                       |                        |                               |  |                                   |

| Blueprint Code and Topic   | Assessment Percentage | Diagnosis/<br>Testing<br>25% | Treatment/<br>Care Decisions<br>60% | Risk Assessment<br>/Prognosis<br>/Epidemiology<br>10% | Pathophysiology<br>/Basic Science<br>5% |
|--|-----------------------|------------------------------|-------------------------------------|---|---|
| 2.4.2 Feeding and nutrition  |                       |                              |                                     |   |   |
| 2.4.3 Decision making/communication  |                       |                              |                                     |   |   |
| <b>2.5 Communication, including prognosis, goals of care, and survivorship</b> | 2%                    | LOW                          | <b>HIGH</b>                         | <b>HIGH</b>   | LOW                                     |
| 2.5.1 Communicating prognosis and other clinical information                   |                       |                              |                                     |   |   |
| 2.5.2 Discussing goals of care   |                       |                              |                                     |   |   |
| 2.5.3 Discussing survivorship issues   |                       |                              |                                     |   |   |
| <b>3 Hematologic Neoplasms</b>   | <b>13%</b>            |                              |                                     |   |   |
| <b>3.1 Acute leukemia and myelodysplasia</b>                                   | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>HIGH</b>   | <b>MEDIUM</b>                           |
| 3.1.1 Acute myeloid leukemia (AML)   |                       |                              |                                     |   |   |
| 3.1.1.1 Acute promyelocytic leukemia (APL)                                     |                       |                              |                                     |   |   |
| 3.1.1.2 AML with recurrent genetic abnormalities                               |                       |                              |                                     |   |   |
| 3.1.1.3 AML with myelodysplasia-related changes                                |                       |                              |                                     |   |   |
| 3.1.1.4 AML not otherwise specified  |                       |                              |                                     |   |   |
| 3.1.1.5 Myeloid sarcoma  |                       |                              |                                     |   |   |
| 3.1.2 Acute lymphoblastic leukemia/lymphoma                                    |                       |                              |                                     |   |   |
| 3.1.3 Myelodysplastic syndromes  |                       |                              |                                     |   |   |
| 3.1.4 Chronic myelomonocytic leukemia  |                       |                              |                                     |   |   |
| <b>3.2 Chronic myeloid leukemia and myeloproliferative neoplasms</b>           | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 3.2.1 Chronic myeloid leukemia   |                       |                              |                                     |   |   |
| 3.2.2 Myeloproliferative neoplasms   |                       |                              |                                     |   |   |
| <b>3.3 Chronic lymphoproliferative leukemias</b>                               | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 3.3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma                  |                       |                              |                                     |   |   |
| 3.3.2 Hairy cell leukemia  |                       |                              |                                     |   |   |
| 3.3.3 T-cell prolymphocytic leukemia   |                       |                              |                                     |   |   |
| 3.3.4 T-cell large granular lymphocytic leukemia                               |                       |                              |                                     |   |   |
| 3.3.5 Monoclonal B-cell lymphocytosis  |                       |                              |                                     |   |   |
| <b>3.4 Hodgkin lymphoma</b>  | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 3.4.1 Early-stage disease  |                       |                              |                                     |   |   |
| 3.4.2 Advanced disease   |                       |                              |                                     |   |   |
| <b>3.5 Multiple myeloma and plasma cell dyscrasias</b>                         | 3%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 3.5.1 Multiple myeloma/plasma cell leukemia                                    |                       |                              |                                     |   |   |
| 3.5.2 Solitary plasmacytoma  |                       |                              |                                     |   |   |
| 3.5.3 Primary amyloidosis  |                       |                              |                                     |   |   |
| 3.5.4 Monoclonal gammopathy of undetermined significance (MGUS)                |                       |                              |                                     |   |   |
| 3.5.5 Lymphoplasmacytic lymphoma (including Waldenstrom macroglobulinemia)     |                       |                              |                                     |   |   |
| <b>3.6 Non-Hodgkin lymphoma</b>  | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 3.6.1 Diffuse large B-cell lymphoma  |                       |                              |                                     |   |   |
| 3.6.2 Follicular lymphoma  |                       |                              |                                     |   |   |
| 3.6.3 Burkitt lymphoma   |                       |                              |                                     |   |   |
| 3.6.4 Mantle cell lymphoma   |                       |                              |                                     |   |   |

| Blueprint Code and Topic   | Assessment Percentage | Diagnosis/<br>Testing<br>25% | Treatment/<br>Care Decisions<br>60% | Risk Assessment<br>/Prognosis<br>/Epidemiology<br>10% | Pathophysiology<br>/Basic Science<br>5% |
|--|-----------------------|------------------------------|-------------------------------------|---|---|
| 3.6.5 NK-T cell lymphoma   |                       |                              |                                     |   |   |
| 3.6.6 Anaplastic large cell lymphoma   |                       |                              |                                     |   |   |
| 3.6.7 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)         |                       |                              |                                     |   |   |
| 3.6.8 Nodal marginal zone lymphoma   |                       |                              |                                     |   |   |
| 3.6.9 Human immunodeficiency virus (HIV)-associated lymphoma   |                       |                              |                                     |   |   |
| 3.6.10 Cutaneous T-cell lymphoma   |                       |                              |                                     |   |   |
| 3.6.11 Primary central nervous system lymphoma   |                       |                              |                                     |   |   |
| 3.6.12 Post-transplantation lymphoproliferative syndromes  |                       |                              |                                     |   |   |
| 3.6.13 Peripheral T-cell lymphoma  |                       |                              |                                     |   |   |
| <b>3.7 Genetics and genomics of hematologic neoplasms</b>  | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| <b>3.8 Complications of hematologic neoplasm treatment</b>   | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| <b>4 Thoracic Cancer</b>   | <b>11.5%</b>          |                              |                                     |   |   |
| <b>4.1 Non-small cell lung cancer</b>  | 4%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>HIGH</b>   | <b>MEDIUM</b>                           |
| 4.1.1 Early-stage disease  |                       |                              |                                     |   |   |
| 4.1.1.1 Resectable disease   |                       |                              |                                     |   |   |
| 4.1.1.2 Unresectable disease   |                       |                              |                                     |   |   |
| 4.1.2 Locally advanced disease   |                       |                              |                                     |   |   |
| 4.1.2.1 Stage IIIA disease   |                       |                              |                                     |   |   |
| 4.1.2.2 Stage IIIB disease   |                       |                              |                                     |   |   |
| 4.1.2.3 Stage IIIC disease   |                       |                              |                                     |   |   |
| 4.1.3 Metastatic disease   |                       |                              |                                     |   |   |
| 4.1.3.1 Adenocarcinoma   |                       |                              |                                     |   |   |
| 4.1.3.2 Squamous cell carcinoma  |                       |                              |                                     |   |   |
| <b>4.2 Small cell lung cancer</b>  | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 4.2.1 Limited disease  |                       |                              |                                     |   |   |
| 4.2.2 Extensive disease  |                       |                              |                                     |   |   |
| <b>4.3 Mesothelioma and thymus cancer</b>  | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | <b>MEDIUM</b>   | <b>LOW</b>                              |
| 4.3.1 Mesothelioma   |                       |                              |                                     |   |   |
| 4.3.2 Thymus cancer  |                       |                              |                                     |   |   |
| <b>4.4 Genetics and genomics of thoracic cancer</b>  | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| <b>4.5 Complications of thoracic cancer treatment</b>  | 2.5%                  | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| <b>5 Breast Cancer</b>   | <b>13.5%</b>          |                              |                                     |   |   |
| <b>5.1 Premalignant conditions and high-risk factors</b>   | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 5.1.1 High-risk histologies (including atypical ductal hyperplasia and atypical lobular hyperplasia) |                       |                              |                                     |   |   |
| 5.1.2 Genetic predispositions  |                       |                              |                                     |   |   |
| <b>5.2 Carcinoma in situ</b>   | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | <b>MEDIUM</b>   | <b>LOW</b>                              |
| <b>5.3 Early stage and locally advanced invasive carcinoma</b>                                       | 3%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | <b>MEDIUM</b>   | <b>MEDIUM</b>                           |
| 5.3.1 HER2-positive disease  |                       |                              |                                     |   |   |
| 5.3.2 HER2-negative, hormone receptor-positive disease   |                       |                              |                                     |   |   |
| 5.3.3 HER2-negative, hormone receptor-negative (triple-negative) disease                             |                       |                              |                                     |   |   |

| Blueprint Code and Topic   | Assessment Percentage | Diagnosis/<br>Testing<br>25% | Treatment/<br>Care Decisions<br>60% | Risk Assessment<br>/Prognosis<br>/Epidemiology<br>10% | Pathophysiology<br>/Basic Science<br>5% |
|--|-----------------------|------------------------------|-------------------------------------|---|---|
| <b>5.4 Inflammatory disease</b>  | <2%                   | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| <b>5.5 Locally recurrent disease</b>   | <2%                   | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| 5.5.1 In-breast recurrence   |                       |                              |                                     |   |   |
| 5.5.2 Chest wall recurrence  |                       |                              |                                     |   |   |
| <b>5.6 Metastatic disease</b>  | 3%                    | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| 5.6.1 HER2-positive metastatic disease   |                       |                              |                                     |   |   |
| 5.6.2 HER2-negative, hormone receptor-positive metastatic disease  |                       |                              |                                     |   |   |
| 5.6.3 HER2-negative, hormone receptor-negative (triple-negative) metastatic disease  |                       |                              |                                     |   |   |
| <b>5.7 Less common clinical scenarios, including tubular carcinoma, male breast cancer, and pregnancy-associated breast cancer</b> | <2%                   | MEDIUM                       | HIGH                                | MEDIUM  | MEDIUM                                  |
| 5.7.1 Tubular carcinoma  |                       |                              |                                     |   |   |
| 5.7.2 Male breast cancer   |                       |                              |                                     |   |   |
| 5.7.3 Pregnancy-associated breast cancer   |                       |                              |                                     |   |   |
| <b>5.8 Genetics and genomics of breast cancer</b>  | <2%                   | MEDIUM                       | MEDIUM                              | MEDIUM  | MEDIUM                                  |
| <b>5.9 Complications of breast cancer treatment</b>  | <2%                   | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| <b>6 Genitourinary Cancer</b>  | <b>12%</b>            |                              |                                     |   |   |
| <b>6.1 Germ cell tumors</b>  | <2%                   | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| 6.1.1 Seminoma   |                       |                              |                                     |   |   |
| 6.1.2 Nonseminoma  |                       |                              |                                     |   |   |
| 6.1.3 Germ cell tumor type not specified   |                       |                              |                                     |   |   |
| <b>6.2 Prostate cancer</b>   | 3%                    | HIGH                         | HIGH                                | HIGH  | MEDIUM                                  |
| 6.2.1 Localized disease  |                       |                              |                                     |   |   |
| 6.2.2 Locally advanced disease   |                       |                              |                                     |   |   |
| 6.2.3 Prostate-specific antigen-only nonmetastatic disease   |                       |                              |                                     |   |   |
| 6.2.3.1 Castration-sensitive disease   |                       |                              |                                     |   |   |
| 6.2.3.2 Castration-resistant disease   |                       |                              |                                     |   |   |
| 6.2.4 Metastatic disease   |                       |                              |                                     |   |   |
| 6.2.4.1 Metastatic castration-sensitive disease  |                       |                              |                                     |   |   |
| 6.2.4.2 Metastatic castration-resistant disease  |                       |                              |                                     |   |   |
| 6.2.5 Special issues in prostate cancer  |                       |                              |                                     |   |   |
| 6.2.5.1 Small cell carcinoma   |                       |                              |                                     |   |   |
| <b>6.3 Renal cell cancer</b>   | 2.5%                  | MEDIUM                       | HIGH                                | MEDIUM  | MEDIUM                                  |
| 6.3.1 Localized disease  |                       |                              |                                     |   |   |
| 6.3.2 Metastatic disease   |                       |                              |                                     |   |   |
| 6.3.3 Non-clear cell histologies   |                       |                              |                                     |   |   |
| <b>6.4 Urothelial and other genitourinary cancers</b>  | 2%                    | HIGH                         | HIGH                                | MEDIUM  | MEDIUM                                  |
| 6.4.1 Bladder cancer   |                       |                              |                                     |   |   |
| 6.4.1.1 Non-muscle invasive disease  |                       |                              |                                     |   |   |
| 6.4.1.2 Muscle-invasive disease  |                       |                              |                                     |   |   |
| 6.4.1.3 Metastatic disease   |                       |                              |                                     |   |   |
| 6.4.2 Upper tract urothelial cancer and urethral cancer  |                       |                              |                                     |   |   |

| Blueprint Code and Topic   | Assessment Percentage | Diagnosis/ Testing 25% | Treatment/ Care Decisions 60% | Risk Assessment /Prognosis /Epidemiology 10% | Pathophysiology /Basic Science 5% |
|--|-----------------------|------------------------|-------------------------------|--|-----------------------------------|
| 6.4.3 Rare histologies   |                       |                        |                               |  |                                   |
| <b>6.5 Adrenal tumors</b>  | <2%                   | LOW                    | MEDIUM                        | LOW  | LOW                               |
| 6.5.1 Adrenocortical carcinoma   |                       |                        |                               |  |                                   |
| 6.5.2 Pheochromocytoma and paraganglioma                                 |                       |                        |                               |  |                                   |
| 6.6 Genetics and genomics of genitourinary cancer                        | <2%                   | MEDIUM                 | MEDIUM                        | MEDIUM                                       | MEDIUM                            |
| 6.7 Complications of genitourinary cancer treatment                      | 2%                    | HIGH                   | HIGH                          | MEDIUM                                       | MEDIUM                            |
| <b>7 Gynecologic Cancer</b>  | <b>5.5%</b>           |                        |                               |  |                                   |
| <b>7.1 Cervical cancer</b>   | <2%                   | MEDIUM                 | MEDIUM                        | MEDIUM                                       | LOW                               |
| 7.1.1 Local-regional disease (stages II and III)                         |                       |                        |                               |  |                                   |
| 7.1.2 Recurrent and metastatic disease                                   |                       |                        |                               |  |                                   |
| <b>7.2 Ovarian, fallopian tube, and primary peritoneal cancers</b>       | 2%                    | MEDIUM                 | HIGH                          | MEDIUM                                       | MEDIUM                            |
| 7.2.1 Epithelial ovarian, fallopian tube, and primary peritoneal cancers |                       |                        |                               |  |                                   |
| 7.2.1.1 Stage I  |                       |                        |                               |  |                                   |
| 7.2.1.2 Stages II-IV   |                       |                        |                               |  |                                   |
| 7.2.2 Nonepithelial ovarian cancers                                      |                       |                        |                               |  |                                   |
| 7.2.3 Low malignant potential (borderline) cancers                       |                       |                        |                               |  |                                   |
| <b>7.3 Uterine sarcoma</b>   | 0%                    | LOW                    | LOW                           | LOW  | LOW                               |
| <b>7.4 Endometrial cancer</b>  | <2%                   | MEDIUM                 | MEDIUM                        | MEDIUM                                       | LOW                               |
| <b>7.5 Genetics and genomics of gynecologic cancer</b>                   | <2%                   | MEDIUM                 | MEDIUM                        | LOW  | LOW                               |
| <b>7.6 Complications of gynecologic cancer treatment</b>                 | <2%                   | MEDIUM                 | MEDIUM                        | LOW  | LOW                               |
| <b>8 Gastrointestinal Cancer</b>   | <b>13.5%</b>          |                        |                               |  |                                   |
| <b>8.1 Anal cancer</b>   | <2%                   | HIGH                   | HIGH                          | MEDIUM                                       | MEDIUM                            |
| 8.1.1 Local-regional disease   |                       |                        |                               |  |                                   |
| 8.1.2 Recurrent and metastatic disease                                   |                       |                        |                               |  |                                   |
| <b>8.2 Biliary tree and gallbladder cancer</b>                           | <2%                   | HIGH                   | HIGH                          | MEDIUM                                       | MEDIUM                            |
| 8.2.1 Local-regional disease   |                       |                        |                               |  |                                   |
| 8.2.2 Recurrent and metastatic disease                                   |                       |                        |                               |  |                                   |
| <b>8.3 Colorectal cancer</b>   | 2%                    | HIGH                   | HIGH                          | HIGH   | MEDIUM                            |
| 8.3.1 Colon cancer   |                       |                        |                               |  |                                   |
| 8.3.1.1 Local-regional disease   |                       |                        |                               |  |                                   |
| 8.3.1.2 Recurrent and metastatic disease                                 |                       |                        |                               |  |                                   |
| 8.3.2 Rectal cancer  |                       |                        |                               |  |                                   |
| 8.3.2.1 Local-regional disease   |                       |                        |                               |  |                                   |
| 8.3.2.2 Recurrent and metastatic disease                                 |                       |                        |                               |  |                                   |
| <b>8.4 Esophageal cancer</b>   | <2%                   | HIGH                   | HIGH                          | MEDIUM                                       | MEDIUM                            |
| 8.4.1 Local-regional disease   |                       |                        |                               |  |                                   |
| 8.4.2 Recurrent and metastatic disease                                   |                       |                        |                               |  |                                   |
| <b>8.5 Gastric cancer</b>  | <2%                   | HIGH                   | HIGH                          | MEDIUM                                       | MEDIUM                            |
| 8.5.1 Resectable disease   |                       |                        |                               |  |                                   |
| 8.5.2 Unresectable and metastatic disease                                |                       |                        |                               |  |                                   |

| Blueprint Code and Topic   | Assessment Percentage | Diagnosis/<br>Testing<br>25% | Treatment/<br>Care Decisions<br>60% | Risk Assessment<br>/Prognosis<br>/Epidemiology<br>10% | Pathophysiology<br>/Basic Science<br>5% |
|--|-----------------------|------------------------------|-------------------------------------|---|---|
| <b>8.6 Hepatocellular cancer</b>   | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| 8.6.1 Resectable disease   |                       |                              |                                     |   |   |
| 8.6.2 Unresectable, liver-only disease   |                       |                              |                                     |   |   |
| 8.6.3 Metastatic disease   |                       |                              |                                     |   |   |
| <b>8.7 Gastrointestinal neuroendocrine tumors</b>  | <2%                   | <b>MEDIUM</b>                | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| <b>8.8 Pancreatic cancer</b>   | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| 8.8.1 Resectable disease   |                       |                              |                                     |   |   |
| 8.8.2 Unresectable disease   |                       |                              |                                     |   |   |
| 8.8.3 Metastatic and recurrent disease   |                       |                              |                                     |   |   |
| <b>8.9 Small bowel and appendiceal cancer</b>  | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| 8.9.1 Small bowel cancer   |                       |                              |                                     |   |   |
| 8.9.2 Appendiceal cancer   |                       |                              |                                     |   |   |
| <b>8.10 Genetics and genomics of gastrointestinal cancer</b>                               | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| <b>8.11 Complications of gastrointestinal cancer treatment</b>                             | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| <b>9 Skin Cancer, Sarcomas, and Unknown Primary Site</b>                                   | 7%                    |                              |                                     |   |   |
| <b>9.1 Melanoma</b>  | 2.5%                  | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| 9.1.1 Localized melanoma   |                       |                              |                                     |   |   |
| 9.1.2 Regional nodal and in-transit metastasis   |                       |                              |                                     |   |   |
| 9.1.3 Metastatic disease   |                       |                              |                                     |   |   |
| <b>9.2 Squamous cell and basal cell cancer of the skin</b>                                 | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | MEDIUM  | LOW                                     |
| 9.2.1 Local-regional disease   |                       |                              |                                     |   |   |
| 9.2.2 Recurrent and metastatic disease   |                       |                              |                                     |   |   |
| <b>9.3 Merkel cell carcinoma</b>   | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | LOW   | LOW                                     |
| <b>9.4 Bone and soft-tissue sarcomas</b>   | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | MEDIUM  | MEDIUM                                  |
| 9.4.1 Localized primary disease  |                       |                              |                                     |   |   |
| 9.4.2 Local disease recurrence   |                       |                              |                                     |   |   |
| 9.4.3 Metastatic disease   |                       |                              |                                     |   |   |
| 9.4.4 Gastrointestinal stromal tumor (GIST)  |                       |                              |                                     |   |   |
| 9.4.4.1 Local-regional disease   |                       |                              |                                     |   |   |
| 9.4.4.2 Recurrent and metastatic disease   |                       |                              |                                     |   |   |
| <b>9.5 Unknown primary site</b>  | <2%                   | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| <b>9.6 Genetics and genomics of skin cancers, sarcomas, and unknown primary site</b>       | <2%                   | <b>MEDIUM</b>                | <b>MEDIUM</b>                       | MEDIUM  | MEDIUM                                  |
| <b>9.7 Complications of treatment for skin cancers, sarcomas, and unknown primary site</b> | <2%                   | <b>MEDIUM</b>                | <b>HIGH</b>                         | MEDIUM  | LOW                                     |
| <b>10 Head, Neck, Thyroid, and Central Nervous System Malignancies</b>                     | 6.5%                  |                              |                                     |   |   |
| <b>10.1 Squamous cell carcinoma of the head and neck</b>                                   | 2%                    | <b>HIGH</b>                  | <b>HIGH</b>                         | MEDIUM  | MEDIUM                                  |
| 10.1.1 Human papillomavirus-positive disease   |                       |                              |                                     |   |   |
| 10.1.1.1 Local-regional disease  |                       |                              |                                     |   |   |
| 10.1.1.2 Recurrent and metastatic disease  |                       |                              |                                     |   |   |
| 10.1.2 Human papillomavirus-negative disease   |                       |                              |                                     |   |   |
| 10.1.2.1 Local-regional disease  |                       |                              |                                     |   |   |

| Blueprint Code and Topic                         | Assessment Percentage | Diagnosis/<br>Testing<br>25% | Treatment/<br>Care Decisions<br>60% | RiskAssessment<br>/Prognosis<br>/Epidemiology<br>10% | Pathophysiology<br>/Basic Science<br>5% |
|--|-----------------------|------------------------------|-------------------------------------|--|---|
| 10.1.2.2 Recurrent and metastatic disease        |                       |                              |                                     |  |   |
| <b>10.2 Salivary gland tumors</b>                | <2%                   | MEDIUM                       | MEDIUM                              | MEDIUM   | LOW                                     |
| <b>10.3 Thyroid cancer</b>                       | <2%                   | MEDIUM                       | MEDIUM                              | MEDIUM   | LOW                                     |
| 10.3.1 Papillary                                 |                       |                              |                                     |  |   |
| 10.3.2 Medullary                                 |                       |                              |                                     |  |   |
| 10.3.3 Anaplastic                                |                       |                              |                                     |  |   |
| <b>10.4 Nasopharyngeal carcinoma</b>             | <2%                   | MEDIUM                       | MEDIUM                              | MEDIUM   | LOW                                     |
| 10.4.1 Local and regional disease                |                       |                              |                                     |  |   |
| 10.4.2 Metastatic disease                        |                       |                              |                                     |  |   |
| <b>10.5 Central nervous system malignancies</b>  | <2%                   | HIGH                         | HIGH                                | MEDIUM   | MEDIUM                                  |
| 10.5.1 Primary central nervous system lesions    |                       |                              |                                     |  |   |
|  |                       |                              |                                     |  |   |
|  |                       |                              |                                     |  |   |
| 10.5.2 Metastatic central nervous system lesions |                       |                              |                                     |  |   |
| 10.5.2.1 Parenchymal metastases                  |                       |                              |                                     |  |   |
| 10.5.2.2 Meningeal metastases                    |                       |                              |                                     |  |   |
|  | <2%                   | MEDIUM                       | MEDIUM                              | MEDIUM   | MEDIUM                                  |
|  | <2%                   | HIGH                         | HIGH                                | MEDIUM   | MEDIUM                                  |